KEYNOTE-522: Phase III study of pembrolizumab (pembro) plus chemotherapy (chemo) vs placebo (pbo) plus chemo as neoadjuvant treatment, followed by pembro vs pbo as adjuvant treatment for early triple-negative breast cancer (TNBC)
Schmid P, Cortes J, Dent R, Pusztai L, Mcarthur HL, Kuemmel S, Bergh J, Denkert C, Park YH, Hui R, Harbeck N, Takahashi M, Foukakis T, Fasching P, Cardoso F, Jia L, Karantza V, Zhao J, Aktan G, O'Shaughnessy J (2019)
Publication Type: Conference contribution
Publication year: 2019
Journal
Publisher: OXFORD UNIV PRESS
City/Town: OXFORD
Pages Range: 853-854
Conference Proceedings Title: ANNALS OF ONCOLOGY
Event location: Barcelona
DOI: 10.1093/annonc/mdz394.003
Authors with CRIS profile
Involved external institutions
Queen Mary University of London
United Kingdom (GB)
IOB Institute of Oncology
Spain (ES)
Kliniken Essen-Mitte
Germany (DE)
University of Toronto
Canada (CA)
Karolinska Institute
Sweden (SE)
Philipps-Universität Marburg
Germany (DE)
Cedars-Sinai Medical Center
United States (USA) (US)
Yale University
United States (USA) (US)
Sungkyunkwan University (SKKU)
Korea, Republic of (KR)
Merck & Co., Inc. / Merck Sharp & Dohme Corp (MSD)
United States (USA) (US)
Baylor University (BU)
United States (USA) (US)
Ludwig-Maximilians-Universität (LMU)
Germany (DE)
Westmead Hospital
Australia (AU)
Champalimaud Foundation / Fundação Champalimaud
Portugal (PT)
United Kingdom (GB)
IOB Institute of Oncology
Spain (ES)
Kliniken Essen-Mitte
Germany (DE)
University of Toronto
Canada (CA)
Karolinska Institute
Sweden (SE)
Philipps-Universität Marburg
Germany (DE)
Cedars-Sinai Medical Center
United States (USA) (US)
Yale University
United States (USA) (US)
Sungkyunkwan University (SKKU)
Korea, Republic of (KR)
Merck & Co., Inc. / Merck Sharp & Dohme Corp (MSD)
United States (USA) (US)
Baylor University (BU)
United States (USA) (US)
Ludwig-Maximilians-Universität (LMU)
Germany (DE)
Westmead Hospital
Australia (AU)
Champalimaud Foundation / Fundação Champalimaud
Portugal (PT)
How to cite
APA:
Schmid, P., Cortes, J., Dent, R., Pusztai, L., Mcarthur, H.L., Kuemmel, S.,... O'Shaughnessy, J. (2019). KEYNOTE-522: Phase III study of pembrolizumab (pembro) plus chemotherapy (chemo) vs placebo (pbo) plus chemo as neoadjuvant treatment, followed by pembro vs pbo as adjuvant treatment for early triple-negative breast cancer (TNBC). In ANNALS OF ONCOLOGY (pp. 853-854). Barcelona, ES: OXFORD: OXFORD UNIV PRESS.
MLA:
Schmid, P., et al. "KEYNOTE-522: Phase III study of pembrolizumab (pembro) plus chemotherapy (chemo) vs placebo (pbo) plus chemo as neoadjuvant treatment, followed by pembro vs pbo as adjuvant treatment for early triple-negative breast cancer (TNBC)." Proceedings of the 44th Congress of the European-Society-for-Medical-Oncology (ESMO), Barcelona OXFORD: OXFORD UNIV PRESS, 2019. 853-854.
BibTeX: Download